Pol Specenier
Impact in
- Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
Papers in
- Oncology 55
- Peptidase Inhibition and Analysis 13
- Cancer Immunotherapy and Biomarkers 11
- HER2/EGFR in Cancer Research 7
-
- Lung Cancer Treatments and Mutations 26
- Co-authors
- Jan B. Vermorken (8 shared papers)Jan B. Vermorken (22 shared papers)Filip Lardon (10 shared papers)Jan B. Vermorken (6 shared papers)Marc Baay (7 shared papers)Vanessa Deschoolmeester (6 shared papers)Marc Peeters (15 shared papers)Ilse Weets (1 shared paper)
- Journals
- Expert Review of Anticancer Therapy (9 papers)Annals of Oncology (7 papers)Journal of Clinical Oncology (6 papers)Cancer Chemotherapy and Pharmacology (4 papers)The Oncologist (4 papers)
- Partner nations
- BelgiumUnited StatesItaly
In The Last Decade
Pol Specenier
81 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 101
- Otorhinolaryngology 450
- Oncology 1.1k
- Cancer Research 261
- Pulmonary and Respiratory Medicine 542
- Genetics 150
Countries citing papers authored by Pol Specenier
This map shows the geographic impact of Pol Specenier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pol Specenier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pol Specenier more than expected).
Fields of papers citing papers by Pol Specenier
This network shows the impact of papers produced by Pol Specenier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pol Specenier. The network helps show where Pol Specenier may publish in the future.
Co-authors
The 25 scholars most cited alongside Pol Specenier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 281 | |
| 2 | 2016 | 204 | |
| 3 | 2018 | 167 | |
| 4 | 2010 | 133 | |
| 5 | 2016 | 83 | |
| 6 | 2013 | 72 | |
| 7 | 2013 | 71 | |
| 8 | 2008 | 71 | |
| 9 | 2014 | 51 | |
| 10 | 2018 | 40 | |
| 11 | 2016 | 36 | |
| 12 | 2011 | 35 | |
| 13 | 2008 | 34 | |
| 14 | 2016 | 30 | |
| 15 | 2007 | 28 | |
| 16 | 2014 | 27 | |
| 17 | 2018 | 25 | |
| 18 | Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. | 2015 | 24 |
| 19 | 2015 | 22 | |
| 20 | 2015 | 21 |
About Pol Specenier
Pol Specenier is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Otorhinolaryngology, Molecular Biology and Surgery, having authored 84 papers that have together received 1.9k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (32 papers), Lung Cancer Treatments and Mutations (26 papers), Peptidase Inhibition and Analysis (13 papers), Cancer Immunotherapy and Biomarkers (11 papers), Melanoma and MAPK Pathways (7 papers), HER2/EGFR in Cancer Research (7 papers), Salivary Gland Tumors Diagnosis and Treatment (7 papers) and Cancer-related gene regulation (6 papers). The work is most often cited by research in Otorhinolaryngology (450 citations), Oncology (1.1k citations), Cancer Research (261 citations), Pulmonary and Respiratory Medicine (542 citations) and Genetics (150 citations). Pol Specenier has collaborated with scholars based in Belgium, United States and Italy. Frequent co-authors include Jan B. Vermorken, Jan B. Vermorken, Filip Lardon, Jan B. Vermorken, Marc Baay, Vanessa Deschoolmeester, Marc Peeters, Ilse Weets, Christophe De Block and An Wouters. Their work appears in journals such as Expert Review of Anticancer Therapy, Annals of Oncology, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.